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Background-—The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society
(ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors
in situations of very high risk. We aim to assess in the real world the suitability of PCSK9 inhibitors for acute coronary syndromes.
Methods and Results-—We analyzed a prospective Swiss cohort of 2023 patients hospitalized for acute coronary syndromes
between 2009 and 2014 with available data for low-density lipoprotein cholesterol and lipid-lowering therapy at 1 year. Clinical
familial hypercholesterolemia was deﬁned using the Dutch Lipid Clinic Network algorithm as unlikely, possible, probable, or
deﬁnite. We simulated a ﬁxed relative reduction of 24% in low-density lipoprotein cholesterol levels at 1 year in all patients not
treated with ezetimibe, irrespective of the low-density lipoprotein cholesterol levels and statin regimen. At 1 year, 94.3% of
patients were treated with statin, 5.8% with ezetimibe, and 35.8% of patients had on-target low-density lipoprotein cholesterol
levels (<1.8 mmol/L); 25.6% met criteria for possible or probable/deﬁnite familial hypercholesterolemia. After a simulation of the
lipid-lowering effect of ezetimibe, the proportion of patients who would be eligible for PCSK9 inhibitors at 1 year was 13.4% using
American College of Cardiology criteria and 2.7% using European Society of Cardiology/European Atherosclerosis Society criteria.
Patients with possible or probable/deﬁnite familial hypercholesterolemia were more eligible for PCSK9 inhibitors compared with
their non–familial hypercholesterolemia counterparts: 27.6% versus 8.8% according to American College of Cardiology criteria and
6.6% versus 1.8% according to European Society of Cardiology/European Atherosclerosis Society criteria (P<0.001).
Conclusions-—Recommendations made by the American College of Cardiology guidelines would lead to 5-fold higher eligibility
rates for PCSK9 inhibitors compared to the European Society of Cardiology/European Atherosclerosis Society consensus
statement in acute coronary syndrome patients. ( J Am Heart Assoc. 2017;6:e006537. DOI: 10.1161/JAHA.117.006537.)
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A lthough long-term prognosis of patients after acutecoronary syndromes (ACS) has considerably improved,
the residual risk remains high with a recurrence rate of
ischemic events of 20% within 3 years.1 Lipid-lowering
therapies, such as statins or ezetimibe, have shown a
reduction of major adverse cardiovascular events in
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secondary prevention after ACS.2,3 European Society of
Cardiology (ESC) guidelines on the management of ACS
recommend decreasing low-density lipoprotein cholesterol
(LDL-C) to a target level of <1.8 mmol/L using high-
intensity statin therapy in combination with ezetimibe if
needed.4,5
However, real-life data suggest that less than one third of
ACS patients are able to reach the recommended targets,
including those treated with high-intensity statin therapy.6 The
reasons for poorly controlled LDL-C levels are statin resis-
tance, lack of therapy intensiﬁcation, or statin intolerance (eg,
statin-associated muscle symptoms).7 The proprotein conver-
tase subtilisin/kexin-9 (PCSK9) inhibitors have emerged as a
promising therapy for the treatment of hypercholesterolemia,
because monoclonal antibodies against PCSK9 lowered LDL-C
by 50% to 60%.8,9 Both alirocumab and evolocumab have been
approved by regulatory agencies for the treatment of primary
hypercholesterolemia in case of poorly controlled LDL-C with
maximal tolerated statin therapy or as a second-line treat-
ment in case of documented statin intolerance.10 After post
hoc analyses suggesting a relative reduction of major adverse
cardiovascular events by 50% for both agents,11,12 the
FOURIER (Further Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated Risk) trial
including 27 564 patients with atherosclerotic cardiovascular
disease (ASCVD) met its primary outcome with a signiﬁcant
reduction of major adverse cardiovascular events by 11.3%
(P<0.001) in the evolocumab arm compared with placebo over
a median follow-up of 2.2 years.13 Recently, both the
American College of Cardiology (ACC) expert consensus
decision pathway on the role of nonstatin therapies for LDL-C
lowering in the management of ASCVD and a joint consensus
statement from the ESC and European Atherosclerosis
Society (EAS) have provided a practical guidance for the use
of PCSK9 inhibitors in patients at very high cardiovascular
risk, such as those with manifest ASCVD, familial hyperc-
holesterolemia (FH), and statin intolerance.10,14 Those state-
ments took an initial position by deﬁning criteria for
consideration of PCSK9 inhibition based on current evidence.
No real-world data are available regarding the eligibility of
PCSK9 inhibitors according to the suggested European and
American criteria and the potential place of those promising
agents in secondary prevention after ACS. Against this
background, we evaluated the suitability of PCSK9 inhibitors
1 year after the index ACS event in a large, contemporary
European population.
Methods
Study Population
The present analysis was performed within the ELIPS
(Multidimensional PreventIon Program After Acute Coronary
Syndrome) study (NCT01075867). ELIPS is a subproject of
the ongoing, prospective, multicenter, and observational
SPUM-ACS (Special Program University Medicine-Acute
Coronary Syndromes) cohort aiming to assess the quality of
care and the adherence to the recommended preventive
targets in 4 academic centers in Switzerland: Bern, Geneva,
Lausanne, and Zurich.6,7,15-17 For this analysis, we considered
all ACS patients who were enrolled between 2009 and 2014
and survived 1 year after the index event hospitalization with
available data on lipid values and lipid-lowering therapies as
well as data on the occurrence of clinical outcomes at 1-year
follow-up. Inclusion criteria were age ≥18 years and index
diagnosis of ST-elevation myocardial infarction (MI), non–ST-
elevation MI, or unstable angina. Exclusion criteria were
limited to severe physical disability or dementia and life
expectancy less than 1 year for noncardiac reasons. The
protocol was approved by local ethical committees. All
patients provided written informed consent.
Lipid-Lowering Medications
Medication before hospitalization, at discharge, and at 1-year
follow-up was systematically collected by trained study
nurses. Intensity of statin therapy was classiﬁed as low,
moderate; or high intensity based on current lipid guidelines
Clinical Perspective
What Is New?
• No study has compared the eligibility for proprotein
convertase subtilisin/kexin-9 inhibitors in patients with
acute coronary syndromes.
• In this large Swiss cohort we observed that 13% of patients
would be eligible for proprotein convertase subtilisin/kexin-
9 inhibitors based on the American College of Cardiology
(ACC) criteria, and 3% based on the European Society of
Cardiology/European Atherosclerosis Society (ESC/EAS)
criteria.
• These differences illustrate the more conservative approach
proposed by the ESC/EAS document.
What Are the Clinical Implications?
• The incremental low-density lipoprotein cholesterol–lower-
ing effect conveyed by pretreatment with ezetimibe would
dramatically reduce the indication for proprotein convertase
subtilisin/kexin-9 inhibitors in both algorithms.
• Identifying acute coronary syndrome patients with familial
hypercholesterolemia based on the Dutch Lipid Clinic
Network clinical score will help clinicians to select patients
who would be more likely to formally qualify for treatment
with proprotein convertase subtilisin/kexin-9 inhibitors.
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(Table S1).5 Physicians were encouraged to prescribe guide-
line-recommended statin treatment at discharge, that is, high-
intensity statin except for patients in whom such regimens
were not deemed appropriate (eg, because of a history of
intolerance, patient characteristics, or concomitant medica-
tions that increased the risk for developing statin-related
adverse events, or in elderly patients). Treating general
practitioners and cardiologists were encouraged not to
discontinue or change statin treatment to lower-intensity
regimens during the follow-up period unless clinically indi-
cated. Consistently, the present analyses were done with the
assumption that patients were on maximally tolerated study
treatment at 1 year. Reasons for nonprescription of statins
were collected at discharge using medical records, as were
reasons for therapy discontinuation at 1 year according to the
patients. At the 1-year follow-up, we also asked patients to
bring the list of medications and the pill boxes to conﬁrm their
statement. Nonstatin lipid-lowering therapies included eze-
timibe, ﬁbrates, niacin, and bile acid resins.
Blood Lipid Measurements and Clinical Diagnosis
of Familial Hypercholesterolemia
At baseline, levels for total cholesterol, high-density lipopro-
tein cholesterol and triglycerides were measured from the
ﬁrst available fasting sample within 24 hours of hospital
admission. LDL-C was calculated using the Friedewald
equation when triglycerides were below 4.5 mmol/L.15 One
year after hospitalization, blood lipid levels were measured at
the scheduled follow-up visit in a fasting-state. Clinical
diagnosis of FH was based on the recommended Dutch Lipid
Clinic Network (DLCN) algorithm (Table S2).15 Variables
included personal and family history of premature cardiovas-
cular disease and LDL-C levels at baseline. Possible FH was
deﬁned by a score 3 to 5 and probable/deﬁnite FH by a score
≥6. For patients taking lipid-lowering medications before
hospitalization, we estimated untreated baseline LDL-C levels
based on the type and dose of medication, applying appro-
priate correcting factors corresponding to the reported
efﬁcacy of each drug. (Table S3).18 As done previously, only
patients with normal triglycerides (<2.3 mmol/L) received
scoring for elevated LDL-C levels as recommended by the
DLCN score for FH diagnosis.15
Eligibility for PCSK9 Inhibitors
On the basis of 1-year LDL-C levels, lipid-lowering therapies,
and clinical outcomes, the eligibility for the use of PCSK9
inhibitors at follow-up was deﬁned according to the following
ESC/EAS criteria: (1) LDL-C ≥3.6 mmol/L (140 mg/dL) at
1 year while on statin in combination with ezetimibe; or (2) LDL-
C ≥2.6 mmol/L (100 mg/dL) at 1 year in case of rapid
progression of ASCVD. In this study, rapid progression of
ASCVD for the ESC/EAS deﬁnition included (1) recurrent MI,
hospitalization for unstable angina, unplanned coronary revas-
cularization or ischemic stroke within 1 year of the index ACS
event; or (2) previous MI, percutaneous coronary intervention,
coronary artery bypass surgery, an ischemic cerebrovascular
event, or peripheral arterial disease before the index event. The
eligibility according ACC criteria was deﬁned: (1) LDL-C
≥2.6 mmol/L (100 mg/dL) while on statin in combination
with ezetimibe and a reduction of LDL-C levels less than 50%
from baseline; or (2) LDL-C ≥1.8 mmol/L (70 mg/dL) while on
statin in combination with ezetimibe and a reduction of LDL-C
levels less than 50% from baseline in case of diabetes mellitus
or an ASCVD event 3 months before follow-up irrespective of
statin therapy at discharge, or at any time during follow-up if on
statin at discharge; or (3) baseline LDL-C ≥4.9 mmol/L
(190 mg/dL) and 1-year LDL-C ≥1.8 mmol/L (70 mg/dL)
while on statin and a reduction of LDL-C levels less than 50%.
Because the use of ezetimibewas infrequent in the present data
set, and because a combination of maximally tolerated statin
plus ezetimibe is a prerequisite for consideration of PCSK9
inhibitor treatment for both the ACC13 and ESC/EAS algo-
rithms,10 the effect of ezetimibe on top of statin was simulated
in all patients not receiving ezetimibe at 1 year. For our main
analyses we implemented a ﬁxed relative reduction of 24% in
LDL-C levels at 1 year in all patients not treated with ezetimibe,
irrespective of the LDL-C levels and statin regimen3; in an
ancillary analysis, a more conservative approach was applied
assuming 18% incremental LDL-C reduction when modeling the
effect of ezetimibe. Clinical end points were adjudicated by a
panel of independent experts (3 certiﬁed cardiologists) blinded
to the results of LDL-C levels.
Study Objectives and Sensitivity Analyses
The primary objective of this analysis was to evaluate the
proportion of patients meeting the criteria for consideration of
PCSK9 inhibition at 1 year according to the ESC/EAS and
ACC consensus statements. The main analysis compared
eligibility for PCSK9 inhibitor treatment according to the ACC
versus ESC/EAS algorithms in all patients who were on any
statin regimen at 1 year and either received ezetimibe at
1 year or in whom the incremental effect of ezetimibe on
1-year LDL-C levels was simulated. Sensitivity analyses were
performed to assess eligibility for PCSK9 inhibitors according
to the statin intensity at 1 year and in 4 additional different
scenarios: in all patients, including those without statin
treatment at 1 year (eg, statin intolerance) (scenario 1);
including patients on statin treatment at 1 year but without
simulating the effect of ezetimibe (scenario 2); including all
patients (ie, also those without statin at 1 year) without
simulating the effect of ezetimibe (scenario 3); and including
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patients who were on any statin regimen at 1 year and
stimulating an 18% LDL-C reduction with ezetimibe (scenario
4). In addition, we assessed the proportion of patients
reaching the LDL-C target <1.8 mmol/L according to statin
intensity and in different scenarios: (1) based on actual 1-year
LDL-C levels in the current cohort; (2) after the simulated
addition of ezetimibe; (3) after the simulated addition of
PCSK9 inhibitors according to the ACC and ESC/EAS
eligibility criteria. To model the incremental effect of PCSK9
inhibitors, we simulated a ﬁxed relative reduction of 50% on
LDL-C levels at 1 year in addition to the incremental effect of
ezetimibe in treatment-eligible patient and not in all patients.8
Statistical Analysis
Continuous variables are summarized as meanstandard
deviation, categorical variables as actual numbers and
percentages. Baseline characteristics, medications, and lipid
levels were compared using the Fisher test for binary
variables, chi-squared for more than 2 responses, or unpaired
t tests as appropriate. PCSK9 inhibitor eligibility was modeled
with mixed-effects logistic regression models with a random
intercept by site. The model included the following predictors:
sex, age, body mass index, FH, and attendance to cardiac
rehabilitation (at discharge or reported at follow-up). Odds
ratios and 95% conﬁdence intervals from multivariate and
univariate models are reported. The analysis was performed
for both ESC/EAS and ACC eligibility criteria. All analyses
were conducted in Stata version 14.1 (Stata Corporation,
College Station, TX) and R version 3.3.1 (R Foundation for
Statistical Computing, Vienna, Austria). The statistical signif-
icance was set at the 0.05 level.
Results
Out of 3027 consecutive patients hospitalized for ACS between
2009 and 2014, 65 died within a 1-year follow-up, 937 had
missing data for LDL-C levels and 2 for statin therapy, yielding a
ﬁnal sample of 2023 patients (Figure 1). Baseline character-
istics for those excluded from the analysis are provided in
Table S4. The mean age was 61.7 years, 80.3% were male,
21.8% had a diagnosis of possible and 3.6% of probable/
deﬁnite FH. The use of statin before hospitalization was 25.9%
(Table 1). Most patients were hospitalized for ST-elevation MI
(56.2%), 92.5% had an index percutaneous coronary interven-
tion, and 71.0% attended a cardiac rehabilitation program. At
1 year, 51 patients (2.5%) had presented with MI, 119 (5.9%)
unplanned revascularization, 26 (1.3%) ischemic cerebrovas-
cular event, and 40 (2.0%) hospitalization for unstable angina.
The use of a statin was 98.5% at discharge and 94.3% at
1 year. The frequencies of high-, moderate-, and low-intensity
statin treatment at discharge and 1 year were, respectively,
65.8% versus 55.3%, 31.9% versus 36.7%, and 0.8% versus
2.2%. (Table 2) Ezetimibe was used in 2.0% of patients at
discharge and in 5.8% at 1 year. The patients’ reported
reasons for discontinuation of statin therapy at 1 year were
mainly attributed to physician decision and side effects of
treatment (Table S5). Among patients who discontinued
statins, 47% reported that treatment was stopped by their
physician (documented statin intolerance probable), 30%
stopped due to side effects (statin intolerance possible),
18% stopped themselves (probable noncompliance), and 5%
stopped for other reasons (eg, costs). Mean LDL-C levels were
3.271.11 mmol/L (126.542.9 mg/dL) at baseline and
2.190.86 mmol/L (84.733.3 mg/dL) at 1 year (P<0.01
using a paired t test). The proportion of patients reaching the
LDL-C <1.8 mmol/L targets at 1 year was 35.8% (Table 3).
The main analysis included patients on any statin treatment at
1 year (1908 of 2023 patients). After modeling the effect of
ezetimibe in all patients not receiving ezetimibe at 1 year,
13.4% and 2.7% of patients were eligible for PCSK9 inhibitors
according to ACC and ESC/EAS guidelines, respectively
(Table 4). Among 258 patients eligible for PCSK9 inhibitors
according to either of the 2 deﬁnitions, 48 (2.3%) were eligible
for both ESC/EAS and ACC criteria, 207 (10.2%) only for ACC
criteria, and 3 (0.2%) only for ESC/EAS criteria (Figure 2). In
456 patients with FH, the proportion who would be eligible for
PCSK9 inhibitors was signiﬁcantly higher compared with their
non-FH counterparts (27.6% versus 8.8% for ACC criteria and
6.6% versus 1.8% for ESC/EAC criteria, P<0.001, Table 5).
The percentage of patients meeting PCSK9 eligibility criteria
increased slightly (16.3% versus 4.1%, respectively) when
those not treated with statin at 1 year (scenario 1) were
included. In regard to actual treatment without modeling the
effect of ezetimibe (scenario 2), the proportion of patients
Figure 1. Study ﬂowchart. ACS indicates acute coronary
syndromes; LDL, low-density lipoprotein cholesterol.
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who met the respective LDL-C cutoffs for ACC and ESC/EAS
criteria for PCSK9-inhibitor eligibility were 31.4% and 10.6%,
respectively, and 34.2% versus 13.2% (scenario 3) including
patients not on statin. Finally, when an 18% LDL reduction
with ezetimibe was modeled in patients on any statin
treatment at 1 year (scenario 4), the proportions of patients
who would be eligible for PCSK9 inhibitors according to ACC
and ESC/EAS guidelines were 16.4% and 4.3%, respectively.
The simulated addition of ezetimibe to all patients with
LDL-C >1.8 mmol/L increased the proportion of patients who
would reach recommended LDL-C targets (<1.8 mmol/L) to
63.7%. After simulation of the effect of PCSK9 inhibitors in
eligible patients, the percentages of patients on target with
LDL-C <1.8 mmol/L in the total cohort were 66.2% using
ESC/EAS criteria and 78.5% using ACC criteria (Figure 3).
Focusing only on patients who were eligible by either of the 2
criteria (n=258), the proportion of those who would be on
target with LDL-C <1.8 mmol/L after simulation of the PCSK9
inhibitor effect was 93%. Figure 3 also depicts the shift in the
distribution of LDL-C with increasing statin intensity and with
the addition of ezetimibe and PCSK9 inhibitors. The mean
LDL-C values would decrease to 1.630.57 and 1.480.45,
respectively, for the ESC/EAS and ACC criteria (Table 3).
Among patients with FH, only 20.0% were on target at 1 year,
but after simulation of the combined effects of ezetimibe and
PCSK9 inhibitors, the proportion of patients who would reach
the LDL-C targets was 50.5% using ESC/EAC criteria and
71.2% using ACC criteria (Table S6).
Patients eligible for PCSK9 inhibitors were more likely to
have possible and probable/deﬁnite FH (odds ratios were
3.99, 95% conﬁdence intervals 2.82 to 5.64 for ACC criteria
and 3.38, 95% conﬁdence interval 1.70 to 6.72 for ESC/EAC
criteria, Table 6). Attendance at cardiac rehabilitation after
hospital discharge was associated with a decrease in PCSK9
Table 1. Baseline Characteristics of the SPUM-ACS Cohort
(N=2023)
Variables Values
Age (y, meanSD) 61.7011.86
Sex (female) 398 (19.7%)
BMI (≥30 kg/m²) 437 (21.6%)
Cardiovascular risk factors
Premature CAD* 660 (32.6%)
Diabetes mellitus 307 (15.2%)
Hypertension 1040 (51.4%)
Current smoker 810 (40.0%)
Family history
of CAD
560 (27.8%)
Previous CVD 441 (21.8%)
MI 254 (12.6%)
PCI 287 (14.2%)
CABG 68 (3.4%)
PAD 78 (3.9%)
Stroke/TIA 70 (3.5%)
CKD (eGFR <60 mL/min) 223 (11.2%)
Familial hypercholesterolemia†
Unlikely 1333 (74.4%)
Possible 392 (21.9%)
Probable 59 (3.3%)
Definite 8 (0.4%)
LDL-C
(mmol/L, meanSD)
3.271.11
Use of statin 523 (25.9%)
Hospital management
ACS diagnosis
STEMI 1136 (56.2%)
NSTEMI 806 (39.9%)
Unstable angina 80 (4.0%)
Revascularization treatment
PCI 1871 (92.5%)
CABG 6 (0.3%)
Conservative 146 (7.2%)
Attendance to CR after hospital discharge 1416 (71.0%)
ACS indicates acute coronary syndromes; BMI, body mass index; CABG, coronary artery
bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; CR, cardiac
rehabilitation; CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate;
LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NSTEMI, non–ST-
elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous
coronary intervention; SPUM-ACS, Special Program University Medicine-Acute Coronary
Syndromes; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.
*Premature CAD deﬁned as age <55 years old in male patients and <60 years old in
female patients.
†231 patients did not receive scoring for LDL-C levels as recommended by the Dutch
Lipid Clinic Network score for FH diagnosis.
Table 2. Lipid-Lowering Therapies of the SPUM-ACS Cohort
(N=2023)
Therapy At Discharge At 1-Year
Statin 1992 (98.5%) 1908 (94.3%)
High-intensity 1326 (65.8%) 1107 (55.3%)
Moderate-intensity 643 (31.9%) 735 (36.7%)
Low-intensity 16 (0.8%) 45 (2.2%)
None 30 (1.5%) 115 (5.7%)
Ezetimibe 41 (2.0%) 118 (5.8%)
Fibrates 1 (0.0%) 9 (0.4%)
Niacin 3 (0.1%) 3 (0.1%)
Resin 1 (0.0%) 0 (0.0%)
SPUM-ACS indicates Special Program University Medicine-Acute Coronary Syndromes.
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eligibility for both algorithms (P<0.001). Additional informa-
tion is available in Tables S7, S8, and Figure S1 on the use of
lipid-lowering therapies over time.
Discussion
In this large prospective cohort of ACS patients with optimal
secondary prevention treatment, we found that the eligibility
for PCSK9 inhibitors 1 year after the index event varies
according to the use of ESC/EAS or ACC eligibility criteria as
well as with the simulated pretreatment condition with
ezetimibe. The ESC/EAS criteria are more conservative than
the ACC criteria, and the use of ezetimibe on top of statin is
associated with a signiﬁcant decrease of the potential use of
PCSK9 inhibitors for both criteria. The proportion of patients
on LDL-C target would increase from 36% with actual
therapies to 64% after simulated addition of ezetimibe and
to 79% after modeling the effect if PCSK9 inhibitors, using
ACC criteria for eligibility. Patients with FH based on the
DLCN score are more likely to be eligible for PCSK9 inhibitors.
Our ﬁndings are the ﬁrst to report the expected clinical impact
of these new recommendations on the use of PCSK9
inhibitors in a real-world ACS population.
In the United States, the 2016 ACC expert consensus
decision pathway on the role of nonstatin therapies for LDL-C
lowering in the management of ASCVD deﬁned a less
stringent LDL-C threshold to consider therapy with PCSK9
inhibitors (2.6 mmol/L versus 3.6 mmol/L) compared with
the ESC/EAS statement, and an even lower LDL-C threshold
(1.8 mmol/L) among patients with comorbidities or rapidly
progressive ASCVD. This explains our ﬁnding of a higher
proportion of eligible patients when we used ACC compared
with ESC/EAS criteria. Both algorithms recommend the use of
ezetimibe prior to considering PCSK9 inhibitors and therefore
limit a more extended use of PCSK9 inhibitors. In Europe, the
aim of the ESC/EAS consensus statement was to ensure
appropriate patient pretreatment before consideration of
PCSK9 inhibition.10 The algorithms recommend identifying
very high-risk patients who would likely beneﬁt from PCSK9
inhibition via an approach lowering LDL-C by at least 50% and
consequently a signiﬁcant absolute risk reduction, while also
taking into account the costs of these innovative treatments
and ﬁnancial restraints in healthcare budgets. This document
deﬁned very high-risk patients as patients with established
ASCVD or with FH without ASCVD, who are likely to have an
absolute risk reduction of more than 2% per year. In addition,
the LDL-C threshold for starting therapy is lower in patients
with accelerated ASCVD (2.6 mmol/L versus 3.6 mmol/L).
These recommendations are currently based on limited data
and are likely to be updated once the results of ongoing
clinical outcomes trials become available.
We have recently shown that patients with clinical FH had
a higher risk of major adverse cardiovascular events after an
ACS.17 For the majority of patients, FH is detected only after
the acute event. The DLCN score is a simple tool that can
be implemented in clinical practice during hospital admission
for ACS or in the outpatient setting during a cardiac
rehabilitation program to identify FH patients earlier and to
discuss with them the potential use of PCSK9 inhibitor in
secondary prevention.15 Our analysis suggests that FH
patients were more frequently able to reach the recom-
mended criteria for considering PCSK9 inhibition. However,
guidelines did not consider systematic screening for FH in
this population, and hospital-based initiation of PCSK9
inhibitors in the acute or subacute phase of ACS has not
been tested so far.19 In addition, our data suggest that
recommended intervention on lifestyle habits, such as
attendance at cardiac rehabilitation, is associated with
improved LDL-C control and a consistent decrease in the
need for PCSK9 inhibitors.
The eligibility for PCSK9 inhibitors depends strongly on
pretreatment with ezetimibe. Our data suggest that ezetimibe
is poorly used at 1 year, probably because the results of
Table 3. Lipid Values at Baseline and 1 Year
Baseline Lipids Values
Cholesterol (mmol/L, meanSD) 5.071.22
HDL-C (mmol/L, meanSD) 1.180.35
LDL-C (mmol/L, meanSD) 3.271.11
LDL-C without drug effect (mmol/L, meanSD) 3.721.34
Triglycerides (mmol/L, meanSD) 1.360.78
Lipids at 1 Year
Cholesterol (mmol/L, meanSD) 4.050.99
HDL-C (mmol/L, meanSD) 1.260.35
LDL-C (mmol/L, meanSD) 2.190.86
LDL-C <1.8 mmol/L (N, %) 724 (35.8%)
LDL-C adding ezetimibe (mmol/L, meanSD) 1.700.69
LDL-C adding ezetimibe <1.8 mmol/L (N, %) 1288 (63.7%)
LDL-C adding ezetimibe and PCSK9
inhibitors (ESC/EAS)
1.630.57
LDL-C <1.8 mmol/L adding ezetimibe and
PCSK9 inhibitors (ESC/EAS) (N, %)
1340 (66.2%)
LDL-C adding ezetimibe and PCSK9
inhibitors (ACC)
1.480.45
LDL-C <1.8 mmol/L adding ezetimibe
and PCSK9 inhibitors (ACC) <1.8 mmol/L (N, %)
1588 (78.5%)
Triglycerides (mmol/L, meanSD) 1.320.70
ACC indicates American College of Cardiology; EAS, European Atherosclerosis Society;
ESC, European Society of Cardiology; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin-9.
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IMPROVE-IT (Improved Reduction of Outcomes: Vytorin
Efﬁcacy International Trial) were published after the time
period of our study. It is likely that, in the future, the use of
ezetimibe will increase following recent recommendations in
guidelines5 to improve the control of LDL-C. However, none of
the PCSK9 clinical trials considered pretreatment with
ezetimibe as an inclusion criterion. Moreover, the long-term
feasibility of using 3 different drugs (statin, ezetimibe plus a
PCSK9 inhibitor) to lower cholesterol is unclear, and adher-
ence of patients to such intensive regimens remains to be
determined. In future guidelines the place of ezetimibe in the
context of poorly controlled dyslipidemias with statin alone
may need to be updated on the basis of outcome data from
the large ongoing clinical trials of PCSK9 inhibitors.
Recently data from the FOURIER trial showed that
inhibition of PCSK9 on a background of statin therapy
lowered LDL-C to ≤0.8 mmol/L and resulted in a 15% relative
reduction in the risk of CVD events.13 In this trial the use of
ezetimibe was low (5%), and the inclusion criterion was an
LDL-C ≥1.8 mmol/L under maximally tolerated statin. These
ﬁndings added strong evidence for the beneﬁt of an intensive
lipid-lowering strategy below current targets in secondary
prevention.13 With these new data, the guidance for the
prescription of PCSK9 inhibitors might become even more
broadly inclusive (eg, without the need of pretreatment with
ezetimibe), and the eligibility rate would become potentially
higher, but this remains to be determined in upcoming
recommendations and guideline documents. Although our
data suggest that a substantial number of patients with ACS
would be eligible for PCSK9 inhibitors, there are gaps in
current evidence for long-term safety and efﬁcacy, including
neurocognitive and immunogenic effects, lower and upper age
limits for treatment, and cost-effectiveness in patient popu-
lations at different levels of cardiovascular risk (eg, coronary
disease with comorbidities, such as diabetes mellitus or
chronic kidney disease).10.
Limitations
Our study has several limitations. Although the ELIPS program
is aimed at optimizing secondary prevention treatments and
although our data indeed suggest good adherence to
recommended therapies, the possibility that some patients
did not receive the maximally tolerated statin doses cannot be
excluded. This limitation was partially addressed in sensitivity
analyses in patients treated with high-intensity statins.
Second, although statin discontinuation was attributed to
medical decision or patient-reported side effects in the
Table 4. Eligibility for PCSK9 Inhibitors According to ACC and ESC/EAS Guidelines
Sensitivity Analysis Total No Statin (N=115)
Low-Intensity
Statin (N=45)*,†
Moderate-Intensity
Statin (N=735)*,†
High-Intensity
Statin (N=1107)*,†
Main analysis: patients on statin and with ezetimibe effect (N=1908)‡
Eligible for ACC 255 (13.4%) . . . 17 (37.8%) 120 (16.3%) 114 (10.3%)
Eligible for ESC/EAS 51 (2.7%) . . . 4 (8.9%) 25 (3.4%) 21 (1.9%)
Scenario 1: including patients without statin and with ezetimibe effect (N=2023)‡
Eligible for ACC 329 (16.3%) 74 (64.3%) 17 (37.8%) 120 (16.3%) 114 (10.3%)
Eligible for ESC/EAS 83 (4.1%) 32 (27.8%) 4 (8.9%) 25 (3.4%) 21 (1.9%)
Scenario 2: patients on statin and without ezetimibe effect (N=1908)‡
Eligible for ACC 599 (31.4%) . . . 31 (68.9%) 257 (35.0%) 304 (27.5%)
Eligible for ESC/EAS 202 (10.6%) . . . 10 (22.2%) 91 (12.4%) 97 (8.8%)
Scenario 3: including patients without statin and without ezetimibe effect (N=2023)‡
Eligible for ACC 692 (34.2%) 93 (80.9%) 31 (68.9%) 257 (35.0%) 304 (27.5%)
Eligible for ESC/EAS 267 (13.2%) 65 (56.5%) 10 (22.2%) 91 (12.4%) 97 (8.8%)
Scenario 4: patients on statin and with modified ezetimibe effect (18% LDL reduction) (N=1908)
Eligible for ACC 313 (16.4%) . . . 20 (44.4%) 147 (20%) 141 (12.7%)
Eligible for ESC/EAS 81 (4.3%) . . . 5 (11.1%) 37 (5%) 37 (3.3%)
ACC indicates American College of Cardiology; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein
convertase subtilisin/kexin-9.
*Missing data for statin potency for 21 patients at 1 year.
†Low-intensity statin was deﬁned as simvastatin 10 mg, pravastatin 10 to 20 mg, ﬂuvastatin 20 to 40 mg. Moderate-intensity statin was deﬁned as atorvastatin 10 to 20 mg, rosuvastatin
5 to 10 mg, simvastatin 20 to 40 mg, pravastatin 40 to 80 mg, ﬂuvastatin 80 mg. High-intensity statin was deﬁned as atorvastatin 40 to 80 mg, rosuvatstain 20 to 40 mg.
‡The ezetimibe effect was deﬁned as a ﬁxed relative reduction of 24% in LDL-C levels at 1 year in all patients not treated with ezetimibe, irrespective of the LDL-C levels and statin
regimen.3
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majority (77%) of these patients (Table S4), the diagnosis of
statin intolerance cannot be established deﬁnitively in those
who stopped statin or never used it or used low- to moderate-
intensity treatment. Our study has the strength to report
reasons for therapy discontinuation, and the presented data
strongly suggest that spontaneous discontinuation by the
patients was infrequent. In addition, the ESC/EAS consensus
statement used the same LDL-C threshold to consider PCSK9
inhibitors in those with or without statin intolerance, and our
results suggest that the addition of patients who discontinued
statin only slightly affected eligibility rates, as the majority of
these patients would be eligible due to LDL-C levels above the
targets.20
Third, because themajority of patients were not treated with
ezetimibe, we had to simulate a ﬁxed effect of ezetimibe based
on previous robust evidence.3 The observed effect in real life of
ezetimibe might be different and not the same in all individuals.
Fourth, rapid ASCVD progression was deﬁned by a recurrent
event within a time frame of 5 years in the ESC/EAS document.
In the present analysis the exact timing of prior CVD events
before hospitalization was not collected. Therefore, we cannot
Figure 3. Upper panel, Proportion of patients reaching recom-
mended LDL-C targets (1.8 mmol/L) 1 year after ACS after
adding expected lipid-lowering effects of ezetimibe and PCSK9
inhibitors. Lower panel, Distribution of LDL-C levels 1 year after
ACS according to statin intensity and after adding expected lipid-
lowering effects of ezetimibe and PCSK9 inhibitors. ACS indicates
acute coronary syndromes; LDL-C, low-density lipoprotein choles-
terol; PCSK9, proprotein convertase subtilisin/kexin-9. To model
the incremental effect of PCSK9 inhibitors, we simulated a ﬁxed
relative reduction of 50% on LDL-C levels at 1 year in addition to
the incremental effect of ezetimibe in eligible patient and not in all
patients.
Table 5. Eligibility for PCSK9 Inhibitors According to FH
Classiﬁcation and ACC or ESC/EAS Guidelines
Sensitivity Analysis
Unlikely FH
(N=1333)*
Possible or
Probable/Deﬁnite
FH (N=459)*,† P Value
Eligible for ACC 117 (8.8%) 108 (27.6%) <0.001
Eligible for ESC/EAS 24 (1.8%) 26 (6.6%) <0.001
ACC indicates American College of Cardiology; EAS; European Atherosclerosis Society;
ESC, European Society of Cardiology; FH, familial hypercholesterolemia; PCSK9,
proprotein convertase subtilisin/kexin-9.
*231 patients did not receive scoring for LDL-C levels as recommended by the Dutch
Lipid Clinic Network score for FH diagnosis.
†22.3% vs 2.2% were eligible for possible FH (N=390), 28.8% vs 16.7% for probable/
deﬁnite FH (N=66).
Figure 2. Venn diagram showing the number of ACS patients
eligible for PCSK9 inhibitors according to the ACC and EAS/ESC
consensus documents. The proportions below the absolute
numbers pertain to the entire cohort (n=2023). ACC indicates
American College of Cardiology; ACS, acute coronary syndromes;
EAS, European Atherosclerosis Society; ESC, European Society of
Cardiology; PCSK9, proprotein convertase subtilisin/kexin-9.
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exclude that a proportion of patients were classiﬁed as rapid
progression of ASCVD although the time frame between the
CVD history and the index ACS events might have been longer
than 5 years in some cases. Fifth, exclusion of patients who
died before 1-year follow-up might introduce a selection bias in
favor of low-risk patients as well as those with missing data for
LDL-C. Finally, beyond formal eligibility criteria, the decision to
consider treatment with PCSK9 inhibitors should be based on
shared decision making between clinicians and individual
patients—a critical process that could not be addressed in the
present study.
Conclusions
In this large cohort of ACS patients treated with recom-
mended preventive treatment, we observed that 13% of
patients would be eligible for PCSK9 inhibitors based on the
ACC criteria, and 3% would be eligible based on the ESC/EAS
criteria. These differences illustrate the more conservative
approach proposed by the ESC/EAS document. The incre-
mental LDL-C–lowering effect conveyed by pretreatment with
ezetimibe would dramatically reduce the indication for PCSK9
inhibitors in both algorithms. Identifying ACS patients with FH
based on the DLCN clinical score will help clinicians to select
patients who would be more likely to formally qualify for
treatment with PCSK9 inhibitors.
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Table S1. Classification of intensity of statin treatment 
according to type and dose of statin. 
 Low-intensity 
• simvastatin 10 mg,  
• pravastatin 10-20mg  
• fluvastatin 20-40 mg 
 Moderate-intensity  
• atorvastatin 10-20mg  
• rosuvastatin 5-10 mg  
• simvastatin 20-40 mg  
• pravastatin 40-80 mg  
• fluvastatin 80 mg 
 High-intensity  
• atorvastatin 40-80mg  
• rosuvastatin 20-40mg 
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Table S2. Dutch Lipid Clinic Network criteria for diagnosis of familial hypercholesterolemia 
(FH). 
Variable Grading 
First degree relative with known premature atherosclerosis OR  with known 
LDL-cholesterol > 95th percentile 
1 point 
Personal history of  premature (< 55 years men; < 60 years women) cerebral or 
peripheral vascular disease 
1 point 
LDL-cholesterol 4.0-4.9 mmol/l* 1 point 
Personal history of premature (< 55 years men; < 60 years women) coronary 
heart disease 
2 points 
First-degree relative with tendon xanthomata and/or arcus cornealis OR child 
below 18 years with LDL-cholesterol > 95th percentile 
2 points 
LDL-cholesterol 5.0-6.4 mmol/l* 3 points 
Presence of arcus cornealis below 45 years 4 points 
LDL-cholesterol 6.5-8.4 mmol/l* 5 points 
Presence of tendon xanthomata 6 points 
LDL-cholesterol > 8.5 mmol/l* 8 points 
Functional mutation in LDL receptor, apo B or PCSK9 gene 8 points 
*Only in patients with triglyceride levels < 2.3 mmol/l. Possible FH: 3-5 points; probable FH: 6-8 points; definite FH >8 points. 
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Table S3. Correction factors for lipid lowering drugs  
 
Lipid-lowering 
treatment 
Dosage (mg) LDL-C reduction in 
percentage 
Correction factor 
Statin    
Atorvastatin 5, 10 37 1.59 
 20 43 1.75 
 40 49 1.96 
 80 55 2.22 
Fluvastatin 20 21 1.27 
 40 27 1.36 
 80 33 1.49 
Pravastatin 10 20 1.25 
 20 24 1.32 
 40, 80 39 1.64 
Rosuvastatin 5 38 1.61 
 10 43 1.75 
 20 48 1.92 
 40 53 2.13 
Simvastatin 5 23 1.3 
 10 27 1.37 
 20 32 1.47 
 40 37 1.59 
 80 42 1.72 
Ezetimibe  10 19 1.23 
Niacin  10 1.11 
Fibrates  13 1.15 
Correction based on Beeseling et al, Atherosclerosis 2014 (219-223)  
Correction factor = 100 / (100-reduction in percentage) 
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Table 4. Baseline Characteristics of the SPUM-ACS cohort (N=3027) 
 Final cohort 
(N=2023) 
Missing (N=1004) P-value 
Age (in years, mean ± SD)                                     61.70 ± 11.86 62.98 ± 13.36 0.008 
Gender (female) 398 (19.7%) 244 (24.3%) 0.004 
BMI (≥ 30 kg/m²) 437 (21.6%) 227 (22.6%) 0.544 
Cardiovascular risk 
factors 
   
Premature CAD *          660 (32.6%) 336 (33.5%) 0.651 
Diabetes  307 (15.2%) 200 (19.9%) 0.001 
Hypertension  1040 (51.4%) 596 (59.4%) < 0.001 
Current smoker 810 (40.0%) 451 (44.9%) 0.011 
Family history of CAD  560 (27.8%) 267 (26.8%) 0.603 
Previous CVD 441 (21.8%) 278 (27.7%) < 0.001 
MI 254 (12.6%) 169 (16.8%) 0.002 
PCI 287 (14.2%) 170 (16.9%) 0.052 
CABG 68 (3.4%) 58 (5.8%) 0.003 
PAD 78 (3.9%) 69 (6.9%) < 0.001 
Stroke/TIA 70 (3.5%) 44 (4.4%) 0.224 
CKD (eGFR < 60 ml/min) 223 (11.2%) 161 (17.0%) < 0.001 
Familial 
hypercholesterolemia † 
   
Unlikely 1333 (74.4%) NA  
Possible 392 (21.9%)   
Probable 59 (3.3%)   
Definite 8 (0.4%)   
LDL-C (mmol/l, mean ± 
SD) 
3.27 ± 1.11 NA  
Use of Statin  523 (25.9%) 299 (30.0%) 0.017 
Hospital management    
ACS diagnosis    
STEMI 1136 (56.2%) 555 (55.4%) 0.697 
NSTEMI 806 (39.9%) 400 (39.9%) 1.000 
Unstable angina 80 (4.0%) 47 (4.7%) 0.337 
Revascularization treatment    
PCI 1871 (92.5%) 896 (89.2%) 0.004 
CABG 6 (0.3%) 2 (0.2%) 1.000 
Conservative 146 (7.2%) 106 (10.6%) 0.002 
Attendance to CR after 
hospital discharge 
1416 (71.0%)   
* Premature CAD defined as age < 55 years old in male and < 60 years old in female. 
† * 231 patients did not  receive scoring for LDL-C levels as recommended by the Dutch Lipid Clinic Network score for FH diagnosis.  
Abbreviations : ACS, acute coronary syndromes; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery 
disease ; CKD, chronic kidney disease; CR, cardiac rehabilitation; CVD, cardiovascular disease ; eGFR, estimated glomerular filtration 
rate; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction ; NA, not available; NSTEMI, Non  ST-elevation 
myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention ; SD, standard deviation ; STEMI, ST-
elevation myocardial infarction; TIA, transient ischaemic attack. 
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Table S5. Reasons for Non Statin Therapy at Discharge And One Year 
 
Reported Reasons for Non Statin Prescription At Discharge (N=30) 
 N (%) 
Statin-associated muscular symptoms * 3 (10%) 
Hepatopathy or elevated liver enzymes 0 
Allergy (e.g. toxidermia) 1 (3.3%) 
Lipids already in the target 1 (3.3%) 
Other lipid-lowering therapy  2 (6.6%) 
To be introduced in outpatient setting 4 (13.3%) 
Patients’ refusal  1 (3.3%) 
No reported reasons 2 (6.6%) 
Patients’ Reported Reasons for Statin Discontinuation At One Year (N=96) 
 N (%) 
Physicians stopped it 45 (47%) 
Side effects 29 (30%) 
Patient stopped it 17 (18%) 
Others (e.g. costs, media,…) 5 (5%) 
* Defined by myopathy, rhabdomyolysis, increased muscle enzymes.  
15 Missing values for reported reasons at discharge. 
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Table S6. Lipid values at baseline and one year in non-FH and FH patients  
Baseline Lipids Non-FH 
(N=1333) 
FH 
(N=459) 
P value 
Cholesterol (mmol/l, mean ± SD) 4.68 ± 1.01 5.85 ± 1.30 <0.001 
HDL-C (mmol/l, mean ± SD) 1.22 ± 0.36 1.17 ± 0.32 0.003 
LDL-C (mmol/, mean ± SD) 2.95 ± 0.90 4.12 ± 1.20 <0.001 
LDL-C without drug effect (mmo/l, mean ± SD) 3.25 ± 0.82 4.95 ± 1.69 <0.001 
Triglycerides (mmol/l , mean ± SD) 1.11 ± 0.49 1.26 ± 0.51 <0.001 
Lipids at one year    
Cholesterol (mmol/l, mean ± SD) 3.91 ± 0.93 4.37 ± 1.08  <0.001 
HDL-C (mmol/l, mean ± SD) 1.30 ± 0.36 1.23 ± 0.32 0.001 
LDL-C (mmol/, mean ± SD) 2.06 ± 0.80 2.51 ± 0.96 <0.001 
LDL-C < 1.8  mmol/l (N, %) 564 (42.3%) 92 (20.0%) <0.001 
LDL-C plus ezetimibe (mmol/l, mean ± SD) 1.59 ± 0.63 1.97 ± 0.76 <0.001 
LDL-C plus ezetimibe < 1.8 mmol/l (N, %) 939 (70.4%) 221 (48.1%) <0.001 
LDL-C plus ezetimibe and PCSK9 inhibitors (ESC/EAS) 1.54 ± 0.55 1.85 ± 0.56  <0.001 
LDL-C < 1.8 mmol/l plus ezetimibe and PCSK9 inhibitors (ESC/EAS) (N, %) 973 (73.0%) 232 (50.5%) <0.001 
LDL-C plus ezetimibe and PCSK9 inhibitors (ACC) 1.42 ± 0.43 1.59 ± 0.46 <0.001 
LDL-C < 1.8 mmol/l plus ezetimibe and PCSK9 inhibitors (ACC) (N, %) 1096 (82.2%) 327 (71.2%) <0.001 
Triglycerides (mmol/l, mean ± SD) 1.22 ± 0.64 1.38 ± 0.73 <0.001 
Abbreviations: ACC, American College of Cardiology; EAS, European Atherosclerosis Society; ESC; European Society of Cardiology; FH, famuilial hypercholesterolemia; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation. 
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Table S7. Number of patients in relation to intensity of statin treatment at discharge and one year. 
Reported numbers pertain to patients with available information regarding statin regimen at discharge 
as well as one year.   
 
Statin regimen at baseline Statin regimen at discharge  
None Low-intensity Moderate-intensity High-intensity 
 None  26 7 446 1013 
 Low-intensity  0 7 16 22 
 Moderate-intensity  3 1 156 138 
 High-intensity   0 1 10 120  
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Table S8. Number of patients in relation to intensity of statin treatment at discharge and one year. 
Reported numbers pertain to patients with available information regarding statin regimen at discharge 
as well as one year.   
 
Statin regimen at discharge Statin regimen at one year 
None Low-intensity Moderate-intensity High-intensity 
 None (n=29) 6 3 16 7 
 Low-intensity (n=15) 3 5 9 2 
 Moderate-intensity (n=639) 52 19 514 138 
 High-intensity (n=1311)  74 23 282 1,121 
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Figure S1. Proportion of patients on no statin, low-, moderate-, and high-intensity statin 
at baseline (prior to index event) and at discharge.  
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